[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.139.201. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1988

Prevention of the Rise in Intraocular Pressure Following Neodymium-YAG Posterior Capsulotomy Using Topical 1% Apraclonidine

Author Affiliations

From The Wilmer Opthalmological Institute and the Department of Ophthalmology, The Johns Hopkins University and Sinai Hospital, Baltimore (Drs Pollack and Robin); and the Departments of Ophthalmology, University of Texas Health Sciences Center, Dallas (Dr Brown); University of Utah, Salt Lake City (Drs Crandall and White); and University of Texas and The Houston Eye Associates, Houston (Dr Stewart).

Arch Ophthalmol. 1988;106(6):754-757. doi:10.1001/archopht.1988.01060130824031
Abstract

• We studied apraclonidine hydrochloride (aplonidine hydrochloride or ALO 2145), an α-agonist, for its effect on the intraocular pressure (IOP) rise following neodymium-YAG posterior capsulotomy (YPC). In a prospective multicentered double-masked study, 63 eyes were pretreated with one drop of either 1% apraclonidine hydrochloride or placebo one hour before performing YPC and again following the laser treatment. The greatest IOP rise in the placebo-treated eyes occurred in the third hour after YPC, when the mean (±SD) IOP rose from a baseline pressure of 16.4 ± 3.7 to 20.8 ± 6.8 mm Hg. In apraclonidine-treated eyes, the IOP fell from a mean of 15.6 ± 3.8 to 12.8 ± 6.0 mm Hg three hours postoperatively. There were five times as many eyes that had an IOP rise greater than 10 mm Hg in the placebo-treated group compared with those treated with apraclonidine. Apraclonidine proved to be highly effective in preventing the rise in IOP following YPC.

×